Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01642173 · ClinicalTrials.gov registry record · Phase 1
Assessment of Coronary Plaque Composition Using Optical Coherence Tomography
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT01642173: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01642173 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01642173, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The investigator's hypothesis is that local activation of the endogenous Lp-PLA2 plays an integral role in early atherosclerosis, and contributes to the mechanism of coronary endothelial dysfunction and to the structural and mechanical properties that characterize plaque vulnerability. Thus, the investigators study will characterize prospectively the correlation between the functional and structural vascular wall properties, and the activity of the Lp-PLA2 pathway.
Interventions
- DEVICE Optical Coherence Tomography (C7 XR Dragonfly )
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01642173
The ClinicalTrials.gov registry entry for NCT01642173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Optical Coherence Tomography (C7 XR Dragonfly ) is the first listed.
NCT01642173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01642173 about?
NCT01642173 is a clinical study titled "Assessment of Coronary Plaque Composition Using Optical Coherence Tomography". The investigator's hypothesis is that local activation of the endogenous Lp-PLA2 plays an integral role in early atherosclerosis, and contributes to the mechanism of coronary endothelial dysfunction and to the structural and mechanical properties that characterize plaque vulnerability. Thus, the inv...
What is the current status of trial NCT01642173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2010-10. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01642173?
The interventions under investigation include: Optical Coherence Tomography (C7 XR Dragonfly ) (DEVICE).
Who is sponsoring clinical trial NCT01642173?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.